The DOI matches its Crossref record.
Cost Effectiveness of Current Approaches to the Control of Retinopathy in Type I Diabetics
Open accessAbstract
Diabetic retinopathy is a leading cause of blindness among working age Americans. The epidemiology of diabetic eye disease has been well described in population-based studies and the effects of laser treatment have been tested in randomized controlled trials. The authors have designed a computer simulation model using the published reports of these studies to predict the medical and economic effects of applying currently accepted methods for the control of diabetic retinopathy to the population of type I diabetics. Recommendations for screening are taken from the Public Health Committee of the American Academy of Ophthalmology. Treatment recommendations and treatment efficacy are drawn from the reports of the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study (ETDRS). Costs of screening and treatment are drawn from published Medicare reimbursement data. Over a 60-year period, the model predicts that proliferative diabetic retinopathy (PDR) requiring panretinal photocoagulation (PRP) will eventually develop in 72% of type I diabetics and macular edema will develop in 42%. If these treatments are delivered as recommended in the clinical trials, the model predicts a cost of $966 per person-year of vision saved from proliferative retinopathy and $1118 per person-year of central acuity saved from macular edema. This is only one seventh of the $6900 average cost of 1 year of Social Security Disability for those disabled by vision loss. Therefore, this model supports the use of federally funded eye care to prevent blindness in medically uninsured diabetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Diabetic Retinopathy: A Position Statement by the American Diabetes Association
Solomon, S. D., Chew, E., Duh, E. J., Sobrin, L., Sun, J. K., VanderBeek, B. L., Wykoff, C. C., & Gardner, T. W. (2017) · Diabetes Care · doi:10.2337/dc16-2641 · Cited by 940
Sinthanayothin, C., Boyce, J. F., Cook, H. L., & Williamson, T. H. (1999) · British Journal of Ophthalmology · doi:10.1136/bjo.83.8.902 · Cited by 778
Racial Differences in the Cause-Specific Prevalence of Blindness in East Baltimore
Sommer, A., Tielsch, J. M., Katz, J., Quigley, H. A., Gottsch, J. D., Javitt, J. C., Martone, J. F., Royall, R. M., Witt, K. A., & Ezrine, S. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111143252004 · Cited by 764
Self-citationOverview of Epidemiologic Studies of Diabetic Retinopathy
Kobrin Klein, B. E. (2007) · Ophthalmic Epidemiology · doi:10.1080/09286580701396720 · Cited by 734
Diabetic Retinopathy Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.025 · Cited by 717
Metadata
- Authors
- Javitt, J. C., Canner, J. K., & Sommer, A.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 1989-02
- Volume
- 96
- Issue
- 2
- Pages
- 255-264
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2071996252
- Cited by
- 177
- References
- 0
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost Effectiveness of Current Approaches to the Control of Retinopathy in Type I Diabetics. https://app.cochat.ai/papers/10.1016/s0161-6420(89)32923-x
- The paper
- Javitt, J. C., Canner, J. K., & Sommer, A. (1989). Cost Effectiveness of Current Approaches to the Control of Retinopathy in Type I Diabetics. Ophthalmology. https://doi.org/10.1016/s0161-6420(89)32923-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.